Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ULK1 | O75385 | 4/20 | 0.37 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22445861 | 0.82 | MAPT (0.47) | KDM4EHPGDCNR1CNR2LMNA | |
| SCHEMBL4225789 | 0.72 | MAPK1 (0.50) | GSK3BAXLMAPK1CNR1CNR2 | |
| SCHEMBL4785792 | 0.71 | JAK2 (0.54) | GSK3BAXLMAPK1KDM4ECNR1 | |
| SCHEMBL173308 | 0.71 | KDM4E (0.65) | GSK3BAXLKDM4EULK1 | |
| SCHEMBL3713571 | 0.70 | NAMPT (0.48) | KDM4EHSD17B10LMNA | |
| SCHEMBL4783785 | 0.69 | CNR1 (0.53) | GSK3BAXLCNR1CNR2 | |
| SCHEMBL761105 | 0.69 | MAPK1 (0.54) | GSK3BAXLMAPK1CNR1CNR2 | |
| SCHEMBL4782452 | 0.68 | JAK2 (0.50) | GSK3BAXLMAPK1KDM4ECNR1 | |
| SCHEMBL6016427 | 0.67 | SMN1; SMN2 (0.53) | GSK3BAXLKDM4EHPGDULK1 | |
| SCHEMBL29190564 | 0.67 | MAPK1 (0.44) | GSK3BAXLMAPK1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2022-05-26 | — | — | US | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | GSK3B 13/4885AXL 3001/4885MAPK1 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.